US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist
  • 673.600
  • -0.670-0.10%
Close Feb 14 16:00 ET
  • 673.600
  • 0.0000.00%
Post 20:01 ET
73.64BMarket Cap17.57P/E (TTM)

About Regeneron Pharmaceuticals Company

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Company Profile

SymbolREGN
Company NameRegeneron Pharmaceuticals
Listing DateApr 2, 1991
Issue Price22.00
Founded1988
CEODr. Leonard S. Schleifer,M.D.,PhD
MarketNASDAQ
Employees15106
Fiscal Year Ends12-31
Address777 Old Saw Mill River Road
CityTarrytown
ProvinceNew York
CountryUnited States of America
Zip Code10591-6707
Phone1-914-847-7000

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Leonard S. Schleifer,M.D.,PhD
  • Co-Chairman of the Board, Co-President and Chief Executive Officer
  • 8.18M
  • Christopher R. Fenimore
  • Executive Vice President, Finance and Chief Financial Officer
  • --
  • Dr. George D. Yancopoulos,M.D.,PhD
  • Co-Chairman of the Board, Co-President and Chief Scientific Officer
  • 7.76M
  • Daniel P. Van Plew
  • Executive Vice President and General Manager, Industrial Operations and Product Supply
  • 8.76M
  • Jason Pitofsky
  • Principal Accounting Officer, Vice President and Controller
  • --
  • Dr. Neil Stahl,PhD
  • Executive Vice President, Research and Development
  • --
  • Joseph J. Larosa
  • Executive Vice President, General Counsel and Secretary
  • --
  • Andrew J Murphy
  • Executive Vice President, Research
  • 8.43M
  • Marion McCourt
  • Executive Vice President, Commercial
  • --
  • Dr. David P. Schenkein, M.D.
  • Director
  • 1.03M
  • Kathryn Guarini, PhD
  • Director
  • 1.03M
  • Dr. N. Anthony Coles, M.D.
  • Independent Director
  • 704.99K
  • Arthur Frederick Ryan
  • Independent Director
  • 724.99K
  • Dr. Michael S. Brown, M.D.
  • Independent Director
  • 728.99K
  • Dr. Joseph L. Goldstein,M.D.
  • Independent Director
  • 709.99K
  • Dr. Bonnie L. Bassler, PhD
  • Independent Director
  • 709.99K
  • Christine A. Poon
  • Lead Independent Director
  • 748.01K
  • Dr. Huda Y. Zoghbi, M.D.
  • Independent Director
  • 714.99K
  • Dr. Craig B. Thompson,M.D.
  • Independent Director
  • 247.79K
  • George L. Sing
  • Independent Director
  • 724.99K

Trending Stocks

Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More